Pembrolizumab has shown significant efficacy for PD-L1-positive NSCLC in clinical trials [5–7], and the Food and Drug Administration in USA approved pembrolizumab for the treatment of metastatic NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.